What the FDA labels say about taking them together
Ketoconazole and mometasone
Mometasone's FDA label of August 19, 2026 names ketoconazole in its drug interactions (prescription label) section; the ketoconazole label PlainMeds reads does not name mometasone. The mometasone label: “After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally inhaled mometasone furoate increased.”
Check it at the source: the ketoconazole FDA label on DailyMed (effective January 28, 2026, E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC); the mometasone FDA label on DailyMed (effective August 19, 2026, L. Perrigo Company).
What does the ketoconazole label say about mometasone?
Ketoconazole's label (effective January 28, 2026) does not name mometasone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ketoconazole), E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC, effective January 28, 2026 (SPL set cad7c647-34a9-4e4e-83b3-8d78e58f588f), via openFDA; the full label on DailyMed
What does the mometasone label say about ketoconazole?
Mometasone label, drug interactions (prescription label)Caution should be exercised when considering the coadministration of mometasone furoate monohydrate nasal spray with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Clinical Pharmacology (12.3) ].
Mometasone label, warningsketoconazole pills (medicine for fungal infection) When using this product
Asmanex Hfa label (Organon LLC, July 7, 2026), drug interactionsAfter oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally inhaled mometasone furoate increased.
Asmanex Hfa label (Organon LLC, July 7, 2026), warnings and precautionsInteractions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of ASMANEX HFA with ketoconazole, and other known strong cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4) inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to mometasone furoate may occur [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].
Source: FDA drug label (Asmanex Hfa, NDA205641), Organon LLC, effective July 7, 2026 (SPL set 0c6d63da-41bc-4894-bead-198e66c848ac), via openFDA
Source: FDA drug label (Nasonex), L. Perrigo Company, effective August 19, 2026 (SPL set 13696a8b-366a-4a5e-adea-d5b7bff9e46f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ketoconazole | Mometasone | |
|---|---|---|
| Labeled for | Fungal infections | Allergies, Asthma |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.249 per gram 2% cream | $0.354 per gram 0.1% cream |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once